Alternative names SB-202190
Description Potent ATP competitive p38 MAPK inhibitor. 3D growth matrix component, promotes long-term organoid growth and can be used in production of gastric organoids. Promotes stability of human pluripotent stem cells. Biological Data
Potent ATP competitive p38 MAPK inhibitor (IC
50 values are 50 and 100 nM for p38α and p38β respectively).
It inhibits TNF, IL-1 and CK1 (approx IC
50 = 0.6 μM) and therefore inhibits CREB phosphorylation. It exhibits little or no activity at CK2.
It displays anti-inflammatory properties and induces apoptosis.
It can also be used as a 3D growth matrix component, promotes long-term organoid growth and can be used in production of gastric organoids.
Also promotes stability of human pluripotent stem cells.
Solubility & Handling
Storage instructions -20°C
Solubility overview Soluble in DMSO (100mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use. Chemical Data
Chemical name 4-[4-(4-Fluorophenyl)-5-(4-pyridiny l)-1 H-imidazol-2-yl]phenol
Molecular Formula C 20H 14N 3OF
PubChem identifier 16759148
InChiKey YKRNPHOBDOUQTG-UHFFFAOYSA-N References for SB 202190
References are publications that support the biological activity of the product
Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. Shanware NP et al (2009) BMB Rep 42(3) : 142-7. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Davies SP et al (2000) Biochem J 351(Pt 1) : 95-105. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. Nemoto S et al (1998) J Biol Chem 273(26) : 16415-20.